accounts key programs include: RELOVAIR(TM), LAMA/LABA ('719/vilanterol (VI)) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc, and its oral Peripheral Mu Opioid Receptor Antagonist (PuMA) program. By...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Theravance to Present at Investor Conferences in June 2011
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account